 Drug Discovery has historically been the most expensive and lengthy step in creating new drugs. SDGRs physics-based software cuts the time in half as well as the costs. Along with being a software company with 80 GMs, 99 customer retention rate and robust growth, they have their preclinical drug pipeline giving them major upside. 